MCID: SFT003
MIFTS: 57

Soft Tissue Sarcoma

Categories: Rare diseases

Aliases & Classifications for Soft Tissue Sarcoma

MalaCards integrated aliases for Soft Tissue Sarcoma:

Name: Soft Tissue Sarcoma 20 58 29 42 17
Non-Rhabdomyosarcoma Soft Tissue Sarcoma 20
Malignant Mesenchymal Tumor 58
Malignant Soft Tissue Tumor 58
Connective Tissue Sarcoma 20
Soft Tissue Sarcomas 36
Sarcoma, Soft Tissue 39
Soft Part Sarcoma 58
Sarcoma 70

Characteristics:

Orphanet epidemiological data:

58
soft tissue sarcoma
Prevalence: 1-5/10000 (Europe);

Classifications:



External Ids:

KEGG 36 H02427
UMLS via Orphanet 71 C0334492 C1261473
Orphanet 58 ORPHA3394
UMLS 70 C1261473

Summaries for Soft Tissue Sarcoma

GARD : 20 Soft tissue sarcoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of the "soft tissues" of the body. These tissues connect, support and surround other body parts and may include muscle, fat, blood vessels, lymph vessels, nerves, tendons and the lining of joints. Many people with early soft tissue sarcoma have no signs or symptoms of the condition. When present, symptoms depend on the location and size of the tumor but may include a palpable lump under the skin, pain, or difficulty breathing. Most cases occur sporadically in people with little to no family history of the condition. People who have previously received radiation therapy and those with certain inherited disorders (such as Gorlin syndrome, Gardner syndrome, Li-Fraumeni syndrome, Tuberous sclerosis, neurofibromatosis type 1, and Werner syndrome ) have an increased risk of developing a soft tissue sarcoma. The best treatment options depend on many factors but may include surgery, chemotherapy, and radiation therapy.

MalaCards based summary : Soft Tissue Sarcoma, also known as non-rhabdomyosarcoma soft tissue sarcoma, is related to malignant fibrous histiocytoma and sarcoma, synovial. An important gene associated with Soft Tissue Sarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Bleomycin and Efavirenz have been mentioned in the context of this disorder. Affiliated tissues include bone, uterus and t cells, and related phenotypes are cardiovascular system and immune system

MedlinePlus : 42 Your soft tissues connect, support, or surround other tissues. Examples include your muscles, tendons, fat, and blood vessels. Soft tissue sarcoma is a cancer of these soft tissues. There are many kinds, based on the type of tissue they started in. They may cause a lump or swelling in the soft tissue. Sometimes they spread and can press on nerves and organs, causing problems such as pain or trouble breathing. No one knows exactly what causes these cancers. They are not common, but you have a higher risk if you have been exposed to certain chemicals, have had radiation therapy, or have certain genetic diseases. Doctors diagnose soft tissue sarcomas with a biopsy. Treatments include surgery to remove the tumor, radiation therapy, chemotherapy, or a combination. NIH: National Cancer Institute

KEGG : 36 Soft-tissue sarcomas (STS) are a rare and heterogeneous group of tumors with mesenchymal origin, including muscle, endothelium, cartilage. Several common STSs have recognized translocations, which represent clinical targets. In addition to translocations, other genomic changes and epigenetic mechanisms have been shown to be involved in the histogenesis of STS as well as other cancers.

Wikipedia : 73 A soft-tissue sarcoma (STS) is a malignant tumour, a type of cancer, that develops in soft tissue. A... more...

Related Diseases for Soft Tissue Sarcoma

Diseases related to Soft Tissue Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 870)
# Related Disease Score Top Affiliating Genes
1 malignant fibrous histiocytoma 32.4 TP53 MKI67 MDM2
2 sarcoma, synovial 32.3 MKI67 MDM2 BCL2
3 bone sarcoma 31.9 VEGFA TP53 MDM2 CSF3
4 muscle cancer 31.8 TP53 MDM2 FGFR4
5 leiomyosarcoma 31.8 VEGFA TP53 MDM2
6 angiosarcoma 31.4 VEGFA TP53 MDM2
7 embryonal sarcoma 31.4 TP53 MKI67 MDM2
8 osteogenic sarcoma 31.2 TP53 TNF MDM2 ABCB1
9 myxofibrosarcoma 31.2 TP53 MKI67 MDM2
10 ewing sarcoma 31.1 VEGFA TP53 MDM2 HIF1A EGFR CSF3
11 gastrointestinal stromal tumor 31.1 VEGFA TP53 MKI67 HIF1A EGFR ABCB1
12 neutropenia 31.0 TP53 TNF CSF3 CRP ABCB1
13 mucositis 31.0 VEGFA CSF3 ABCB1
14 connective tissue disease 31.0 VEGFA TP53 TNF IFNG CRP
15 stomatitis 30.9 TNF IFNG CSF3
16 malignant peripheral nerve sheath tumor 30.9 TP53 MDM2 HIF1A EGFR
17 doxorubicin induced cardiomyopathy 30.8 EGFR CSF3
18 fasciitis 30.7 TP53 TNF IFNG
19 li-fraumeni syndrome 30.5 TP53 MDM2 EGFR BCL2
20 undifferentiated embryonal sarcoma of the liver 30.4 TP53 MDM2
21 b-cell lymphoma 30.3 TP53 MKI67 MDM2 BCL2
22 rhabdomyosarcoma 30.3 VEGFA TP53 TNF MDM2 FGFR4 EGFR
23 cellulitis 30.3 TNF CSF3 CRP
24 suppressor of tumorigenicity 3 30.3 TP53 BCL2
25 inflammatory myofibroblastic tumor 30.3 TP53 MKI67 MDM2 BCL2
26 diarrhea 30.2 TNF IFNG EGFR CSF3 ABCB1
27 lymphoma, non-hodgkin, familial 30.2 TP53 MDM2 CSF3 BCL2 ABCB1
28 chordoma 30.1 VEGFA TP53 EGFR
29 lymph node disease 30.1 TNF IFNG CRP
30 osteonecrosis 30.1 VEGFA TNF HIF1A ABCB1
31 pyomyositis 30.1 CSF3 CRP
32 acute graft versus host disease 30.1 TNF IFNG CSF3
33 aspergillosis 30.1 TNF IFNG CSF3
34 cervix carcinoma 30.0 TP53 EGFR ABCB1
35 intravascular papillary endothelial hyperplasia 30.0 VEGFA HIF1A
36 papilledema 30.0 VEGFA TP53 CRP
37 paralytic ileus 30.0 CRP ABCB1
38 neurofibroma 30.0 VEGFA TP53 EGFR
39 hepatic veno-occlusive disease 29.9 VEGFA CSF3 ABCB1
40 toxic shock syndrome 29.9 TNF IFNG EGFR CRP
41 thymoma 29.9 VEGFA TP53 EGFR
42 meningioma, familial 29.9 VEGFA TP53 MKI67 EGFR
43 peripheral vascular disease 29.9 VEGFA TP53 CRP
44 thyroid gland follicular carcinoma 29.9 VEGFA TP53 EGFR
45 appendicitis 29.9 TNF IFNG CSF3 CRP
46 skeletal tuberculosis 29.9 TNF IFNG CRP
47 lymphoma 29.8 TP53 MDM2 EGFR CSF3 BCL2 ABCB1
48 glioma 29.8 TP53 MDM2 EGFR BCL2
49 erythema nodosum 29.8 TNF IFNG CRP
50 pancreatic adenocarcinoma 29.8 VEGFA TP53 MDM2 EGFR

Graphical network of the top 20 diseases related to Soft Tissue Sarcoma:



Diseases related to Soft Tissue Sarcoma

Symptoms & Phenotypes for Soft Tissue Sarcoma

MGI Mouse Phenotypes related to Soft Tissue Sarcoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 ABCB1 BCL2 CRP EGFR HIF1A IFNG
2 immune system MP:0005387 10.31 ABCB1 BCL2 CRP CSF3 EGFR FGFR4
3 hematopoietic system MP:0005397 10.3 ABCB1 BCL2 CSF3 EGFR FGFR4 HIF1A
4 homeostasis/metabolism MP:0005376 10.29 ABCB1 BCL2 CRP EGFR FGFR4 HIF1A
5 growth/size/body region MP:0005378 10.27 ABCB1 BCL2 EGFR FGFR4 HIF1A IFNG
6 cellular MP:0005384 10.26 BCL2 EGFR FGFR4 HIF1A IFNG MDM2
7 digestive/alimentary MP:0005381 10.24 ABCB1 BCL2 EGFR HIF1A IFNG MDM2
8 endocrine/exocrine gland MP:0005379 10.23 ABCB1 BCL2 EGFR HIF1A IFNG MDM2
9 craniofacial MP:0005382 10.2 BCL2 EGFR HIF1A IFNG MDM2 TNF
10 embryo MP:0005380 10.19 BCL2 EGFR HIF1A IFNG MDM2 TNF
11 integument MP:0010771 10.18 BCL2 CSF3 EGFR HIF1A IFNG MDM2
12 neoplasm MP:0002006 10.11 BCL2 EGFR FGFR4 HIF1A IFNG MDM2
13 liver/biliary system MP:0005370 10.1 ABCB1 EGFR HIF1A IFNG MDM2 TNF
14 nervous system MP:0003631 10.09 ABCB1 BCL2 EGFR HIF1A IFNG MDM2
15 muscle MP:0005369 10.08 BCL2 EGFR HIF1A IFNG MDM2 TNF
16 no phenotypic analysis MP:0003012 10.01 ABCB1 EGFR IFNG MDM2 MKI67 TNF
17 limbs/digits/tail MP:0005371 9.99 EGFR HIF1A MDM2 TNF TP53 VEGFA
18 renal/urinary system MP:0005367 9.92 BCL2 CSF3 EGFR HIF1A IFNG MDM2
19 normal MP:0002873 9.91 EGFR HIF1A IFNG MDM2 MKI67 TP53
20 reproductive system MP:0005389 9.91 ABCB1 BCL2 EGFR FGFR4 IFNG MDM2
21 respiratory system MP:0005388 9.7 EGFR FGFR4 HIF1A IFNG TNF TP53
22 skeleton MP:0005390 9.56 EGFR FGFR4 HIF1A IFNG MDM2 TNF
23 vision/eye MP:0005391 9.23 BCL2 EGFR FGFR4 HIF1A IFNG TNF

Drugs & Therapeutics for Soft Tissue Sarcoma

Drugs for Soft Tissue Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 508)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
2
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
3
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
4
Lopinavir Approved Phase 4 192725-17-0 92727
5
Nevirapine Approved Phase 4 129618-40-2 4463
6
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
7
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
8
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
9
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616
10
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
11
tannic acid Approved Phase 4 1401-55-4
12
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
13
Tranexamic Acid Approved Phase 4 1197-18-8 5526
14
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
15
Dalteparin Approved Phase 4 9005-49-6
16
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
17
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
18
Enoxaparin Approved Phase 4 9005-49-6 772
19
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
20 Reverse Transcriptase Inhibitors Phase 4
21 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
22 Antifungal Agents Phase 4
23 Coagulants Phase 4
24 Antifibrinolytic Agents Phase 4
25 Hemostatics Phase 4
26 Anticoagulants Phase 4
27 Fibrinolytic Agents Phase 4
28 Heparin, Low-Molecular-Weight Phase 4
29 calcium heparin Phase 4
30 Antipyretics Phase 4
31 Platelet Aggregation Inhibitors Phase 4
32
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
33
Zidovudine Approved Phase 3 30516-87-1 35370
34
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
35
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
36
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 441300 65140
37
Panitumumab Approved, Investigational Phase 3 339177-26-3 50070211
38
Olaparib Approved Phase 3 763113-22-0 23725625
39
Palbociclib Approved, Investigational Phase 3 571190-30-2 5005498 5330286 11431660
40
Trametinib Approved Phase 3 871700-17-3 11707110
41
Ceritinib Approved Phase 3 1032900-25-6
42
Dabrafenib Approved, Investigational Phase 3 1195765-45-7 44462760 44516822
43
Lapatinib Approved, Investigational Phase 3 231277-92-2, 388082-78-8 208908 9941095
44
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
45
Olaratumab Approved, Investigational Phase 3 1024603-93-7
46
Bortezomib Approved, Investigational Phase 3 179324-69-7 93860 387447
47
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
48
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
49
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
50
Daunorubicin Approved Phase 3 20830-81-3 30323

Interventional clinical trials:

(show top 50) (show all 1417)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma Completed NCT03514381 Phase 4 Patients starting a treatment with Doxorubicin and Ifosfamide
3 A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
4 A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
5 Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule Recruiting NCT04223583 Phase 4 Anlotinib Hydrochloride
6 Prospective, Randomized Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
7 Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib - a Randomized, Controlled Trial Recruiting NCT03735758 Phase 4 pazopanib or guideline conform chemotherapy
8 Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years Recruiting NCT04033081 Phase 4
9 Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction: A Randomized Controlled Trial Recruiting NCT04347122 Phase 4 Tranexamic Acid (TXA)
10 Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma: a Randomized Controlled Trial Recruiting NCT04448873 Phase 4 Sirolimus
11 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
12 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
13 Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
14 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
15 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
16 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
17 A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma Unknown status NCT02449343 Phase 2, Phase 3 Anlotinib;Placebo
18 EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92] Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
19 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
20 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
21 A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005] Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
22 Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
23 European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
24 Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS) Unknown status NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
25 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
26 A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
27 Establishment of an Indication-based Identification and Psychosocial Treatment of Orthopedic Cancer Patients Suffering From Psychosocial Stress Completed NCT01631175 Phase 3
28 Ph III Random Trial of 120-Min Infusion Gemcitabine v. 90-Min Infusion Gemcitabine + Docetaxel in Unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North Amer. Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
29 A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
30 A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients With Metastatic Soft-Tissue or Bone Sarcomas Completed NCT00538239 Phase 3 ridaforolimus;Placebo
31 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
32 A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
33 A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma. Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
34 A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
35 A Randomized Phase III Trial Comparing Trabectedin (Yondelis®) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma Completed NCT02672527 Phase 3 Trabectedin;Dexamethasone
36 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
37 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
38 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
39 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
40 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
41 A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma Completed NCT00001300 Phase 3 doxorubicin;ifosfamide;mesna
42 A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies. Completed NCT00699517 Phase 3 OMBRABULIN (AVE8062);Placebo
43 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
44 Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
45 A Placebo-Controlled Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT00000994 Phase 3 Zidovudine
46 A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma Completed NCT00002445 Phase 3 IM862
47 Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma Completed NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
48 Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
49 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
50 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate

Search NIH Clinical Center for Soft Tissue Sarcoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Ifosfamide
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Genetic Tests for Soft Tissue Sarcoma

Genetic tests related to Soft Tissue Sarcoma:

# Genetic test Affiliating Genes
1 Soft Tissue Sarcoma 29

Anatomical Context for Soft Tissue Sarcoma

MalaCards organs/tissues related to Soft Tissue Sarcoma:

40
Bone, Uterus, T Cells, Endothelial, Bone Marrow, Lymph Node, Myeloid

Publications for Soft Tissue Sarcoma

Articles related to Soft Tissue Sarcoma:

(show top 50) (show all 12652)
# Title Authors PMID Year
1
PLCG2 as a potential indicator of tumor microenvironment remodeling in soft tissue sarcoma. 42 61
33725976 2021
2
Rab11-mediated focal adhesion turnover in sarcoma cell migration. 42
33642343 2021
3
Musculoskeletal Oncology: Patient Triage and Management during the COVID-19 Pandemic. 42
33704139 2020
4
Bioinformatics analysis reveals the competing endogenous RNA (ceRNA) coexpression network in the tumor microenvironment and prognostic biomarkers in soft tissue sarcomas. 61
33587010 2021
5
Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma. 61
33747210 2021
6
Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. 61
33522706 2021
7
Postmarketing observational study of pazopanib in patients with metastatic soft tissue sarcoma in Japan. 61
33283234 2021
8
Reconstruction of upper limb soft-tissue defects after sarcoma resection with free flaps: A systematic review. 61
33277214 2021
9
Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study. 61
32974853 2021
10
Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives. 61
33289402 2021
11
Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study. 61
32419618 2021
12
Lower Extremity Reconstruction After Soft Tissue Sarcoma Resection. 61
33674052 2021
13
Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas. 61
33684876 2021
14
Correlation between cytologic features and histologic grades in cutaneous and subcutaneous soft tissue sarcomas in dogs-A pilot study. 61
33797110 2021
15
Soft tissue sarcoma in adolescent and young adult patients: a retrospective study using a nationwide bone and soft tissue tumor registry in Japan. 61
33791777 2021
16
Paediatric soft tissue sarcomas in a resource constraint setting: Grade and stage at presentation and at oncologic intervention are usually of poor prognostic characteristics. 61
33342027 2021
17
The value of re-staging chest CT at first local recurrence of extremity and trunk soft tissue sarcoma. 61
33037910 2021
18
A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. 61
32956651 2021
19
The Ki-67 proliferation index predicts recurrence-free survival in patients with dermatofibrosarcoma protuberans. 61
33091330 2021
20
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature. 61
32838682 2021
21
Comments About Patterns of Prior and Subsequent Neoplasms in Children and Adolescents With Soft Tissue Sarcomas. 61
33165186 2021
22
In Reply: Comments About Patterns of Prior and Subsequent Neoplasms in Children and Adolescents With Soft Tissue Sarcomas. 61
33181584 2021
23
Sarcomas in the groin and inguinal canal: A 16-year single-centre experience. 61
33455868 2021
24
Treatment Concepts and Challenges in Nonrhabdomyosarcoma Soft Tissue Sarcomas. 61
33706905 2021
25
Intracranial metastasis from a malignant peripheral nerve sheath tumor in a patient with neurofibromatosis type 1: A case study and literature review. 61
33607580 2021
26
Epizootic neoplasia in a managed population of Atlantic bumper fish, Chloroscombrus chrysurus (Osteichthyes: Carangidae), at a public aquarium. 61
33348452 2021
27
Pathological fractures of the femur after radiation therapy for soft tissue tumor: a case series of seven patients treated with repeated internal fixation. 61
32705379 2021
28
Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma. 61
33196586 2021
29
Comparison of clinicopathological features and outcomes in patients with primary leiomyosarcoma of bone and soft tissue. 61
33524203 2021
30
Giant extradural spinal schwannoma in a non-neurofibromatosis child-case report and review of literature. 61
32671532 2021
31
Management of Rhabdomyosarcoma in Pediatric Patients. 61
33706904 2021
32
ASO Author Reflection: Demographic Conditions are the Major Determinants for Functional Outcome and Quality of Life in Lower Extremity Soft Tissue Sarcoma Patients. 61
33651213 2021
33
Risk Factors for Wound Complications After Soft Tissue Sarcoma Resection. 61
33234885 2021
34
Larotrectinib followed by selitrectinib in a novel DCTN1-NTRK1 fusion undifferentiated pleomorphic sarcoma. 61
32693686 2021
35
Primary stromal sarcoma of breast: A case report and literature review. 61
33720870 2021
36
Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. 61
33216382 2021
37
MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma. 61
33564073 2021
38
Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. 61
33306276 2021
39
Suggestion for Research Design: Noninferiority Design in Elderly Patients With Soft-Tissue Sarcoma. 61
33439745 2021
40
Evaluation of head and neck soft tissue sarcoma 8th edition pathologic staging system and proposal of a novel stage grouping system. 61
33422859 2021
41
Corrigendum to 'Soft tissue sarcoma of the hand: Is unplanned excision a problem? [Eur J Surg Oncol 45/7 (2019) 1281-1287]. 61
33678518 2021
42
[Primary alveolar soft tissue sarcoma of the brain and lung: report of two cases]. 61
33677896 2021
43
MRI Tail Sign in Soft-Tissue Sarcoma. 61
33724067 2021
44
Pathologic Response Rates after Neoadjuvant Therapy for Sarcoma: A Single Institution Study. 61
33802383 2021
45
External validation and adaptation of a dynamic prediction model for patients with high-grade extremity soft tissue sarcoma. 61
33332599 2021
46
Prognostic factors and impact of surgery in patients with metastatic soft tissue sarcoma at diagnosis: A population-based cohort study. 61
33774673 2021
47
Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma. 61
33763294 2021
48
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma. 61
33789622 2021
49
Outcomes of Vascular Resection and Reconstruction in Extremity Soft Tissue Sarcoma and Bone Tumors. 61
33795550 2021
50
[Solitary locoregional metastasis of an undifferentiated pleomorphic sarcoma in the M. quadratus femoris]. 61
33733296 2021

Variations for Soft Tissue Sarcoma

Expression for Soft Tissue Sarcoma

Search GEO for disease gene expression data for Soft Tissue Sarcoma.

Pathways for Soft Tissue Sarcoma

Pathways related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 VEGFA TP53 TNF MDM2 IFNG HIF1A
2
Show member pathways
13.74 VEGFA TP53 TNF MDM2 HIF1A FGFR4
3
Show member pathways
13.63 TP53 TNF IFNG FGFR4 EGFR CSF3
4
Show member pathways
13.5 VEGFA TP53 TNF IFNG FGFR4 EGFR
5
Show member pathways
13.37 TP53 TNF MDM2 FGFR4 EGFR CSF3
6
Show member pathways
13.08 VEGFA TP53 TNF IFNG HIF1A FGFR4
7
Show member pathways
12.85 VEGFA TP53 MDM2 EGFR BCL2
8
Show member pathways
12.82 VEGFA TP53 TNF MDM2 HIF1A EGFR
9
Show member pathways
12.81 TP53 TNF MDM2 IFNG BCL2
10 12.75 VEGFA TP53 TNF FGFR4 EGFR
11
Show member pathways
12.64 TP53 TNF IFNG EGFR
12
Show member pathways
12.59 VEGFA TP53 TNF MDM2 FGFR4 EGFR
13
Show member pathways
12.58 TNF IFNG HIF1A EGFR
14
Show member pathways
12.57 TNF IFNG HIF1A BCL2
15
Show member pathways
12.57 TP53 TNF IFNG EGFR BCL2
16
Show member pathways
12.54 VEGFA TP53 MDM2 HIF1A EGFR BCL2
17
Show member pathways
12.49 TP53 TNF FGFR4 EGFR
18
Show member pathways
12.47 VEGFA TP53 MDM2 FGFR4 EGFR
19
Show member pathways
12.41 IFNG EGFR CSF3 BCL2
20
Show member pathways
12.41 TP53 MDM2 FGFR4 EGFR BCL2
21 12.4 VEGFA TP53 MDM2 EGFR BCL2 ABCB1
22 12.36 TP53 TNF MDM2 EGFR BCL2
23
Show member pathways
12.33 TP53 TNF IFNG CRP
24
Show member pathways
12.29 VEGFA TP53 HIF1A EGFR
25
Show member pathways
12.25 TP53 MDM2 HIF1A BCL2
26
Show member pathways
12.25 TP53 TNF IFNG FGFR4 EGFR
27
Show member pathways
12.21 TP53 MDM2 FGFR4 EGFR BCL2
28 12.14 VEGFA TP53 TNF IFNG EGFR
29 12.08 VEGFA TP53 MDM2 EGFR BCL2
30 12.07 TP53 MDM2 EGFR BCL2
31 12.05 VEGFA TP53 TNF MDM2 HIF1A EGFR
32 12 TP53 MDM2 HIF1A
33 12 TP53 TNF BCL2
34 12 TP53 TNF IFNG EGFR
35 12 VEGFA TP53 TNF IFNG BCL2
36 11.98 TNF IFNG CSF3
37 11.98 TP53 MDM2 BCL2
38 11.96 TP53 MDM2 EGFR
39 11.95 VEGFA TP53 MDM2 IFNG HIF1A FGFR4
40 11.93 TP53 MDM2 IFNG BCL2
41 11.91 VEGFA TNF BCL2
42 11.87 VEGFA TNF IFNG
43 11.86 VEGFA TP53 TNF HIF1A BCL2
44 11.81 TP53 MDM2 IFNG
45 11.8 VEGFA IFNG HIF1A EGFR BCL2
46 11.76 TP53 MDM2 BCL2
47
Show member pathways
11.73 VEGFA HIF1A EGFR
48 11.73 TP53 HIF1A EGFR
49 11.72 VEGFA TP53 MDM2 EGFR
50 11.7 VEGFA TP53 MDM2 BCL2

GO Terms for Soft Tissue Sarcoma

Cellular components related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.35 TP53 MDM2 HIF1A EGFR BCL2
2 nuclear body GO:0016604 8.92 TP53 MKI67 MDM2 HIF1A

Biological processes related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 VEGFA TP53 TNF MDM2 HIF1A EGFR
2 negative regulation of apoptotic process GO:0043066 9.99 VEGFA TP53 MDM2 HIF1A EGFR BCL2
3 response to drug GO:0042493 9.97 TP53 MDM2 BCL2 ABCB1
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 VEGFA TNF FGFR4 EGFR
5 positive regulation of protein phosphorylation GO:0001934 9.91 VEGFA TNF IFNG EGFR
6 negative regulation of gene expression GO:0010629 9.91 VEGFA TP53 TNF MDM2 IFNG HIF1A
7 response to oxidative stress GO:0006979 9.88 TP53 EGFR BCL2
8 positive regulation of inflammatory response GO:0050729 9.85 TNF IFNG EGFR
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 VEGFA TP53 CSF3
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.85 VEGFA TNF CSF3
11 positive regulation of protein kinase B signaling GO:0051897 9.85 VEGFA TNF FGFR4 EGFR CSF3
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 VEGFA TNF IFNG
13 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.82 VEGFA TNF MDM2
14 positive regulation of MAP kinase activity GO:0043406 9.81 VEGFA TNF EGFR
15 positive regulation of protein localization to plasma membrane GO:1903078 9.8 TNF IFNG EGFR
16 humoral immune response GO:0006959 9.8 TNF IFNG BCL2
17 cellular response to hypoxia GO:0071456 9.8 VEGFA TP53 MDM2 HIF1A BCL2
18 cytokine-mediated signaling pathway GO:0019221 9.8 VEGFA TP53 TNF HIF1A CSF3 BCL2
19 positive regulation of cell proliferation GO:0008284 9.8 VEGFA MDM2 IFNG FGFR4 EGFR CSF3
20 positive regulation of protein complex assembly GO:0031334 9.79 VEGFA TNF IFNG
21 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.77 TP53 TNF HIF1A
22 positive regulation of chemokine production GO:0032722 9.75 TNF IFNG HIF1A
23 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.7 TNF IFNG
24 positive regulation of DNA biosynthetic process GO:2000573 9.7 VEGFA FGFR4
25 cardiac septum morphogenesis GO:0060411 9.7 TP53 MDM2
26 negative regulation of reactive oxygen species metabolic process GO:2000378 9.7 TP53 HIF1A BCL2
27 digestive tract morphogenesis GO:0048546 9.69 HIF1A BCL2
28 positive regulation of signaling receptor activity GO:2000273 9.69 IFNG HIF1A
29 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.69 TP53 EGFR
30 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.68 TP53 TNF
31 negative regulation of amyloid-beta clearance GO:1900222 9.68 TNF IFNG
32 response to salt stress GO:0009651 9.67 TP53 TNF
33 response to iron ion GO:0010039 9.67 MDM2 HIF1A BCL2
34 negative regulation of lipid storage GO:0010888 9.66 TNF CRP
35 cellular response to UV-C GO:0071494 9.65 TP53 MDM2
36 vascular endothelial growth factor production GO:0010573 9.65 TNF HIF1A
37 astrocyte activation GO:0048143 9.65 TNF IFNG EGFR
38 T cell lineage commitment GO:0002360 9.64 TP53 BCL2
39 B cell lineage commitment GO:0002326 9.62 TP53 BCL2
40 cellular response to actinomycin D GO:0072717 9.59 TP53 MDM2
41 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 TNF IFNG
42 regulation of thymocyte apoptotic process GO:0070243 9.57 TP53 HIF1A
43 positive regulation of vitamin D biosynthetic process GO:0060557 9.56 TNF IFNG
44 positive regulation of nitrogen compound metabolic process GO:0051173 9.55 TNF IFNG
45 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.54 VEGFA TP53 HIF1A
46 negative regulation of mitotic cell cycle GO:0045930 9.46 TP53 TNF EGFR BCL2
47 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.35 VEGFA TNF EGFR CSF3 BCL2
48 positive regulation of gene expression GO:0010628 9.23 VEGFA TP53 TNF MDM2 IFNG HIF1A

Molecular functions related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 VEGFA TP53 TNF MDM2 EGFR CRP
2 protease binding GO:0002020 9.58 TP53 TNF BCL2
3 protein phosphatase binding GO:0019903 9.54 TP53 EGFR BCL2
4 p53 binding GO:0002039 9.5 TP53 MDM2 HIF1A
5 cytokine activity GO:0005125 9.46 VEGFA TNF IFNG CSF3
6 enzyme binding GO:0019899 9.35 TP53 MDM2 HIF1A EGFR CSF3
7 ubiquitin protein ligase binding GO:0031625 9.1 TP53 MDM2 HIF1A EGFR BCL2 ABCB1

Sources for Soft Tissue Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....